Mark Treherne

Mark Treherne is a prominent figure in the biopharmaceutical industry, currently serving as the Chairperson at Monument Therapeutics. He has over 25 years of experience focused on the discovery and development of treatments for diseases with significant unmet medical needs, particularly in neurodegenerative conditions such as Parkinson's and Alzheimer's diseases.13

Professional Background

• Education: Mark holds a BSc, MPhil, and PhD in receptor neuropharmacology from Cambridge University.
• Previous Experience: He has worked extensively in the field, including a notable tenure at Pfizer, where he led research initiatives in neurodegenerative diseases. He founded Cambridge Drug Discovery in 1997, which was sold to BioFocus in 2001. Additionally, he has been involved with several early-stage biotechnology companies and served as Chairman of ERBI (now One Nucleus).12
• Publications: Mark is an accomplished author with over 70 publications in scientific and trade journals, reflecting his deep engagement with the scientific community.1

Current Roles

In addition to his role at Monument Therapeutics, Mark Treherne is also the Chairperson at Talisman Therapeutics and Ubiquigent Ltd., among other companies. His leadership positions highlight his influence and commitment to advancing biopharmaceutical innovations.24